Disclosure Of Interests In Other Entities [Text Block]

OSE Immunotherapeutics - Filing #5980970

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31
Disclosure of interests in other entities [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	—	—	—	—	69 932 EUR	—	—	—	—	—	30 478 EUR	—	—	—	—
Non-current assets	—	—	—	—	54 027 EUR	—	—	—	—	—	51 576 EUR	—	—	—	—
Current liabilities	—	—	—	—	20 221 EUR	—	—	—	—	—	18 799 EUR	—	—	—	—
Non-current liabilities	—	—	—	—	39 927 EUR	—	—	—	—	—	40 280 EUR	—	—	—	—
Profit (loss)	—	37 445 EUR	—	—	—	—	37 445 EUR	—	23 003 EUR	—	—	—	23 003 EUR	—	—
Comprehensive income	- EUR	37 425 EUR	- EUR	- EUR	—	15,000 EUR	37 410 EUR	- EUR	23 089 EUR	- EUR	—	- EUR	23 012 EUR	77,000 EUR	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Other comprehensive income	—	20,000 EUR	—	—	—	—	—	—	86,000 EUR	—	—	—	—	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	—	—	—	—	16 745 EUR	—	—	—	—	—	18 672 EUR	—	—	—	25 620 EUR
Tax expense (income)	—	2 387 EUR	—	—	—	—	—	—	219,000 EUR	—	—	—	—	—	—